109 Million Dollar Investment Atkinsréalis to Provide Design for Sterile Injectable Unit

Related Vendors

Glatt Ingenieurtechnik GmbH

Pörner Ingenieurgesellschaft mbH

Italvacuum, Srl

Atkinsréalis has been chosen by major pharmaceutical contract manufacturer Jubilant Hollisterstier to provide detailed design for the expansion of its sterile injectable facility in Montreal, Canada. The 109 million-dollar facility is a part of Canada’s Biomanufacturing and Life Sciences Strategy pandemic preparedness plan to domestically manufacture and supply vaccines.

Montreal/Canada – Atkinsréalis Group, a world-class engineering services and nuclear company with offices around the world, has won a mandate from Jubilant Hollisterstier, a leading global pharmaceutical contract manufacturer, to provide detailed design for the expansion of their sterile injectable facility in Montreal as part of Canada’s Biomanufacturing and Life Sciences Strategy pandemic preparedness plan to domestically manufacture and supply vaccines.

“Our life sciences and pharmaceutical capabilities are in demand and helping improve health outcomes in the communities we serve,” commented Ian L. Edwards, President and Chief Executive Officer, Atkinsréalis. “We operationalize our purpose of engineering a better future for our planet and its people by working with clients in this space to ramp up their facilities to deliver cutting-edge medicine in a post-pandemic world. Having completed prior phases of work on this project for Jubilant Hollisterstier, this new mandate is an endorsement of the quality of our service level, innovation, and expertise.”

Atkinsréalis’ Industrial team will provide an integrated end-to-end solution for this phase of the project, including design and professional engineering services for the facility and its manufacturing processes. Previous project mandates by Atkinsréalis included concept design and preliminary engineering. The new spaces are expected to be operational by late 2026.

The upgrades to the facility will increase its “fill and finish capacity” by over 100 %. Fill and finishing refers to the process of filling vials with vaccine and finishing the process of packaging and labelling the vaccines for distribution. Expanding the already 40,000 sq. ft facility will create a world-class sterile manufacturing site, offering a wide range of fill and finish capabilities with flexibility in format, type (live, mRNA, and inactivated/subunit) and batch sizes. This flexible manufacturing platform is important as it will allow the facility to address future health emergencies by producing multiple forms of vaccines for various diseases, whether existing or novel.

“Being chosen to support a project that will strengthen Canadian biomedical self-sufficiency to better position the country for future global health events is a privilege,” said Stéphanie Vaillancourt, President, Canada, Atkinsréalis.

The facility’s expansion will generate contract development and manufacturing activities for other Quebec biopharmaceutical companies across the life sciences supply chain. Jubilant Hollisterstier’s expansion is partially funded by the Government of Canada’s Strategic Innovation Fund, as well as by the province of Quebec.

(ID:50152870)